Registration for a live webinar on 'Innovative Vaccines and Viral Pathogenesis: Insights from Recent Monkeypox (Mpox) Research' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Learning objectives
- Kinases are highly prevalent molecules in the genome (1)
- Kinases are highly prevalent molecules in the genome (2)
- Addition of a phosphate adds negative charge
- The transfer of phosphates drives kinase signaling
- Phosphatases remove phosphates
- RTKs and growth fractor receptors
- Complexity of cell signaling
- ErbB receptor family: introduction
- A subset of cancers will overexpress HER2
- Monoclonal antibodies (cell surface targets)
- Antibody binding can have a two-tiered affect
- Trastuzumab
- Antibody-drug conjugates targeting HER2
- ErbB receptor family: EGFR
- Wildtype EGFR
- EGFR activation by mutation in lung cancer
- Mutated EGFR signals without ligand
- Types of kinase inhibitors
- Types of tyrosine kinase inhibitors (TKIs)
- ErbB receptor family: RAS
- RAS becomes activated by mutation in cancers
- RAS is a GTPase
- Sotorasib can inhibit the G12C mutant of RAS
- BRAF signaling
- V600 mutations in BRAF
- Summary
- Increased specificity leads to increased resistance
Topics Covered
- Kinase signaling
- HER2 amplification and overexpression in cancer
- Therapeutic antibodies
- Antibody-drug conjugates
- Activation of EGFR by somatic mutation
- Kinase inhibitors
- MAPK-ERK pathway
Talk Citation
Wendt, M. (2022, September 29). Receptor tyrosine kinase signaling and targeted therapies [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved November 21, 2024, from https://doi.org/10.69645/ZLIJ6924.Export Citation (RIS)
Publication History
Financial Disclosures
- Prof. Michael Wendt has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Other Talks in the Series: The Molecular Basis of Cancer
Transcript
Please wait while the transcript is being prepared...
0:00
Welcome everybody to this talk
on receptor tyrosine
kinase signaling
and the targeted
therapies thereof.
Today we're going to
focus particularly
on two receptor
tyrosine kinases,
some downstream
signaling pathways
that are important in cancer,
initiation in
cancer progression,
those being eGFR and then
its partner in crime, HER2.
By way of introduction,
my name is Mike Wendt,
I'm an associate professor
here at the College of
Pharmacy at Purdue
University in Indiana.
0:29
The learning objectives for
today will be to understand
the basic concepts involved
in kinase signaling,
briefly review the idea
of the transferring of
of gamma phosphate on ATP
to a substrate molecule via
the action of a kinase.
We'll want to understand
the fundamental concepts,
or components of major
pathways activated
activated by receptor tyrosine
kinase (RTK) signaling.
We'll focus mostly on two
major downstream pathways
and some targeted
therapies thereof.
We want to be able to
connect the concepts of
mutational activation,
molecular diagnostics,
leading to the application
of targeted therapies
that we discussed.
This is really a
personalized medicine and
represents a beautiful
synergy between genetics,
medicinal chemistry,
and then the clinical
application of these therapies.
Finally, we will
understand some successes
of combination therapies,
we'll briefly visit the
idea of combining some of
the kinase inhibitors
that we'll talk about
and the successes and
potential failures thereof.
1:31
Kinases are highly prevalent
molecules in the genome.
Nearly 500 kinases have
been characterized
throughout our genome.
Based on sequence similarity,
potentially 900
kinases might exist.
If we look at this dendrogram,
we can see that a large
family of these kinases
are indeed these
tyrosine kinases.
Molecules that transfer
a gamma phosphate from
ATP onto a tyrosine residue
of a substrate molecule.
A large part of these
tyrosine kinase families is
those kinases that lie
on the plasma membrane,
and therefore are receptor
tyrosine kinases.
A very important large
class of molecules
that become dysregulated
during cancer,
leading to things associated
with cancer progression.
Things like proliferation,
increased survival,
migration and so
on and so forth.